• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PLRZ

    Polyrizon Ltd.

    Subscribe to $PLRZ
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Polyrizon Ltd.

    DatePrice TargetRatingAnalyst
    See more ratings

    Polyrizon Ltd. SEC Filings

    View All

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/19/25 8:39:02 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/17/25 4:15:26 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/4/25 4:15:17 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    8/14/25 8:39:22 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    7/31/25 4:19:46 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Polyrizon Ltd.

    S-8 - Polyrizon Ltd. (0001893645) (Filer)

    7/24/25 4:15:49 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    7/22/25 9:12:14 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    7/15/25 7:58:02 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    6/30/25 4:15:29 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    6/12/25 7:35:03 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Ltd. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

    Ra'anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, and regulatory pathways. This submission represents a significant progress in Polyrizon's regulatory strategy, paving the way for potential marketing clearance and addressing a critical

    9/19/25 8:15:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

    Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis. The evaluation was led by Professor Fabio Sonvico from the Department

    9/12/25 7:26:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Regains Compliance with Nasdaq Listing Requirements

    Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the "Hearings Advisor") of the Office of the General Counsel of the Nasdaq Hearings Panel (the "Nasdaq Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements. In a letter dated August 13, 2025, the Hearings Advisor informed the Company that it has demonstrated compliance with the minimum bid price requirement for continued listing set

    8/14/25 8:14:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

    Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis. The evaluation was led by Professor Fabio Sonvico from the Department o

    7/22/25 8:32:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Retains Nasdaq Listing Following Hearings Panel

    Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Nasdaq Hearings Panel (the "Panel") granting the Company's request for the continued listing of its securities on the Nasdaq Capital Market. As previously reported by the Company on May 23, 2025, the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") issued a public interest determination under Listing Rule 5101, citing the Company's issuance of securities in a private placement (the "Priva

    7/15/25 7:55:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

    Ra'anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon's hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery. The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the U

    6/12/25 7:32:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Receipt of Nasdaq Delisting Notice

    Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), stating that based on its review of the Company's public filings with the Securities and Exchange Commission (the "SEC"), its staff has determined to delist the Company's securities pursuant to its discretionary authority under Listing Rule 5101. The receipt of the Nasdaq notification letter does not result in the immediate delisting of the

    5/23/25 4:15:00 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

    The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform. The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa as a surrogate for human nasal tissues. The research aimed to characterize two ke

    5/21/25 7:10:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

    Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse

    5/13/25 7:45:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

    Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.  Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local tolerability, a critical benchmark in the product development roadmap. The study was designed to assess local tolerance and tissue response following a 4-hour application of a formulation

    4/25/25 7:37:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Ltd. Leadership Updates

    Live Leadership Updates

    View All

    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

    Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

    12/19/24 7:22:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

    Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

    12/13/24 6:25:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care